USFDA delays at Monroe and Goa facilities
Monroe facility has an FDA meeting in September 2024, but no restart timeline; Goa remediation completed but inspection pending. Delays could impact US launches.
high · analyst_question
Glenmark Pharmaceuticals Limited — Q1 FY25
Glenmark's Q1 FY25 consolidated revenue grew 6.9% YoY to INR 32,442 million, driven by strong India (11.9% YoY) and Europe (21.4% YoY) performance, while US remained soft.
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
GLP-1 market shift post-2026
Semaglutide patent expiry in 2026 may shift patients from liraglutide to newer GLP-1s, potentially limiting liraglutide's revenue potential.
medium · management_commentaryWorking capital increase
CFO guided working capital days to increase to ~75 days from current 62 days, driven by business growth and receivables, which could pressure cash flows.
medium · management_commentary